0.00Open0.03Pre Close0 Volume14 Open Interest12.00Strike Price0.00Turnover0.00%IV58.92%PremiumDec 6, 2024Expiry Date0.00Intrinsic Value100Multiplier-5DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma252.33Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Recursion Pharmaceuticals Stock Discussion
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class Cdk7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
No comment yet